The Lupold laboratory focuses on prostate cancer biology with the goal of exploiting prostate tissue-specificity to develop new diagnostic, prognostic and therapeutic agents.
Research projects stem from basic cancer biology—such as studying the role of microRNAs in the prostate cancer phenotype—to translational projects, such as targeted siRNA and gene therapy.
One area of interest is high-diversity polymer libraries, including aptamers and peptides, which can be screened to identify high-affinity cancer ligands.
Using this approach, Dr. Lupold developed the first RNA aptamers targeted to a cancer cell-surface antigen. He and others have applied these PSMA-targeting aptamers to deliver various therapeutic and imaging packages to prostate cancer cells and tumors.
Dr. Lupold is involved in additional research projects that focus on prostate cancer biology and developing experimental diagnostic and therapeutic agents for urologic cancers.
He also co-holds four patents related to his research.
View all on Pubmed
Lupold SE., Hicke B.J., Lin Y., Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 62(14):4029-33, 2002.
An androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth. Cancer Research. 69(18): 7165-9, 2009. PMCID: PMC2861586.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi1 AH, Chowdhury WE, Kudrolli TA, Yegnasubramanian A, Luo J, Rodriguez T, Mendell JT, Lupold SE. miR-23.Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. Journal of Clinical Investigation. J Clin Invest. 2011 Jun 1; 121(6):2383-90. PMCID: PMC3104752
Ribas J*, Ni X*, Castanares M, Liu M, Rodriguez R, Mendell JT, and Lupold SE. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res. 2012 Aug 1;40(14):6821-33. PMCID: PMC3413119
Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, and Lupold SE. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Res 2015 Apr 30;43(8):4075-86. PMCID: PMC4417178
Compositions and methods for detecting and quantifying circulating tumor cells (CTCs)
Patent # USPA 20140017668
Compositions and methods for retargeting virus constructs
Patent # USPA 20130315870
Radiation sensitization agents for prostate cancer
Patent # 20130123566
Compositions and methods for generating and screening adenoviral libraries
Patent # USPA 20090074658
Adenoviral fiber exchange shuttle system
Patent # US 8,088,621
Peptides for Targeting the Prostate Specific Membrane Antigen
Patent # US 7,749,986
Nucleic Acid Ligands to the Prostate Specific Membrane Antigen
Patent # US 6,933,114